Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionGsa Capital Partners Llp
Latest Disclosed Ownership2,990 shares
Latest Disclosed Value $ 989
Gsa Capital Partners Llp ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 8, 2026 - Gsa Capital Partners Llp filed a 13F-HR form disclosing ownership of 2,990 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $854,243 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 0 shares of Alnylam Pharmaceuticals, Inc.. The current value of the position is $778,895 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,990 2,990 1 0.0615
2026-02-06 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -476 -100.00 0 0.0000
2025-11-07 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 476 476 0 0.0181
2025-05-08 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,360 -100.00 0 -100.00
2025-02-07 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,360 1,500 52.45 1 0.0760
2024-11-05 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,860 1,018 55.27 1 0.0594
2024-08-15 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,842 1,842 0 0.0313
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,042 -100.00 0 0.0000
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,042 1,042 0 0.0207
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,239 -100.00 0 -100.00
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,239 1,239 248 0.0329
2022-08-09 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,554 -100.00 0 -100.00
2022-05-11 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,554 2,554 417 0.0560
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,732 -100.00 0 -100.00
2021-08-05 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,732 1,122 69.69 463 103.96 0.0521
2021-05-10 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,610 1,610 227 0.0377
2018-08-09 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,573 -100.00 0 -100.00
2018-05-11 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,573 2,573 306 0.0162
2017-11-20 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -7,206 -100.00 0 -100.00
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,206 7,206 575 0.0375
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -3,959 -100.00 0 -100.00
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,959 -2,864 -41.98 268 -29.29 0.0144
2016-08-04 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,823 3,099 83.22 379 61.97 0.0210
2016-05-11 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,724 -701 -15.84 234 -43.88 0.0149
2016-02-09 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,425 -42,499 -90.57 417 -88.94 0.0204
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 46,924 2,256 5.05 3,771 -29.57 0.1854
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,668 39,770 811.96 5,354 947.75 0.2056
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,898 -7,185 -59.46 511 -56.40 0.0203
2015-02-05 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,083 12,083 0.00 1,172 0.0818
2014-11-06 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -7,839 -100.00 0 -100.00
2014-08-08 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,839 -12,261 -61.00 495 -63.33 0.0223
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,100 20,100 1,350 0.0960
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.